AOD-9604 Research & Studies
Part of the full AOD-9604 guide - a growth-hormone c-terminal lipolytic fragment analogue reference compound, identity-verified with a COA on every vial.
In brief
The research framing for AOD-9604 in this dataset is narrow and explicitly preclinical: adipocyte and rodent metabolic-signaling models used to characterize the hGH 176-191 lipolytic domain in isolation from whole-hormone growth-hormone-receptor activity. The literature attributed to this entry is limited to the sources provided below; no additional studies, numbers, or claims are introduced here.
The detail
A closer look
01
Defined research areas
The entry specifies three research areas. First, adipocyte lipolysis-signaling models centered on the beta-3 adrenergic (beta3-AR) pathway. Second, GH-receptor-independent metabolic-fragment studies, examining metabolic signaling that does not route through the growth-hormone receptor. Third, structure-activity work on the hGH 176-191 domain, the parent C-terminal lipolytic region that AOD-9604 is modeled on. These three areas together describe a program focused on isolating and characterizing a single signaling domain of growth hormone rather than studying the intact hormone.
02
Cited primary literature
The single primary citation provided is Heffernan, M. A., et al. (2001), 'The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice,' published in Endocrinology (DOI 10.1210/endo.142.12.8522; PMID 11713213). This study is the source that connects AOD-9604's lipolytic readout to the beta3-AR pathway, because its design contrasts the lipolytic fragment in standard obese-mouse models against beta(3)-AR knockout animals. It is a rodent lipid-metabolism study, and the entry frames it strictly as preclinical receptor/metabolic-signaling characterization.
03
Supporting reference hints in the dataset
Beyond the primary citation, the keyFacts carry source hints rather than full references: the 16-amino-acid length (hGH 176-191 analogue) is attributed to Wikipedia / Particle Peptides; the molecular formula C78H123N23O23S2 to ChemicalBook; and the 'lipolytic without IGF-1 stimulation in models' signaling note to the general AOD-9604 literature. These hints are descriptive provenance for identity and signaling facts, not independent studies, and should be treated as such. No human-trial, dosing, or outcome literature is present in this entry, and none is asserted.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. AOD-9604 is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.